[Biochemical characteristics of the anti-ischemic action of the new structural analog of gamma-butyrobetaine 3-(2,2,2,-trimethylhydrazine)propionate].
A structural analogue of gamma-butyrobetaine 3-(2,2,2-trimethylhydrazine)propionate (THP) administered orally in doses of 50 and 150 mg/kg for 10 days prevented isoproterenol-induced increase of the activity of the hepatic isoform of lactate dehydrogenase in the rat blood serum and in a dose of 150 mg/kg prevented an increase of creatine phosphokinase activity. Against a background of the course administration of THP isoproterenol failed to cause the accumulation of acyl-insoluble acylcarnitine in the myocardium. In this case a dose-dependent decrease of free carnitine concentration and accumulation of fatty acids in the myocardium were noted. The cardioprotective effect of THP manifested itself in prevention of a decrease of ATP and ADP concentrations, accumulation of AMP and a reduction of energy charge under the influence of isoproterenol. The ability of THP to decrease the intracellular concentration of free carnitine and to depress as a result carnitine-dependent oxidation of free fatty acids may underlie the anti-ischemic effect of THP.
D000818:Animals; D002331:Carnitine / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008763:Methylhydrazines / Q000627:therapeutic use*; D009206:Myocardium / Q000378:metabolism; D051381:Rats
D005230:Fatty Acids, Nonesterified; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate; D007545:Isoproterenol; D002331:Carnitine
Biokhimicheskaia kharakteristika antiishemicheskogo deĭstviia novogo strukturnogo analoga gamma-butirobetaina 3-(2,2,2-trimetilgidraziniĭ)propionata.